Chance Pharmaceuticals raises $30m in Series C for inhalation therapies
Chance Pharmaceuticals, a Chinese clinical-stage biotech company focused on inhalation therapies for debilitating diseases, has raised $30 million in a Series C financing round. The funding round of the Chinese pharma company was led by new investor Lapam Capital, a healthcare-focused venture capital firm based in China, as per an announcement made in October 2021. […]